Clinical trial
Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).
NCT00502034 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).
- Lead sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 1994
- Completion date
- June 30, 2012
- Enrollment
- 310 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.